ResearcherTongji HospitalActive in the last 2 years

Fang Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9771-184X; OpenAlex author ID A5087840516. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

CXCL11 recruits immunosuppressive cells to form a barrier at the invasive front of pancreatic cancer by activating the NF-κB/CCL2 axis. Co-author DOI 10.1016/j.tranon.2026.102909 ↗
FAM111B and FANCD2, a dual expression signature, defines a distinct phenotype of pancreatic cancer. Co-author DOI 10.1186/s12935-025-03819-6 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xianglin Yuan · 2 shared papers, 2025–2026 · strength 0.64
- Paper CXCL11 recruits immunosuppressive cells to form a barrier at the invasive front of pancreatic cancer by activating the … DOI 10.1016/j.tranon.2026.102909 ↗
- Paper FAM111B and FANCD2, a dual expression signature, defines a distinct phenotype of pancreatic cancer. DOI 10.1186/s12935-025-03819-6 ↗
Zuhua Wang · 1 shared paper, 2026 · strength 0.33
- Paper CXCL11 recruits immunosuppressive cells to form a barrier at the invasive front of pancreatic cancer by activating the … DOI 10.1016/j.tranon.2026.102909 ↗
Lihong Zhang · 1 shared paper, 2025 · strength 0.30
- Paper FAM111B and FANCD2, a dual expression signature, defines a distinct phenotype of pancreatic cancer. DOI 10.1186/s12935-025-03819-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.